

WHONET

Introduction



**WHO Collaborating Centre for
Surveillance of Antimicrobial Resistance**

Boston, July 2022

WHONET – Introduction

This tutorial includes the following sections.

- Part 1. What is WHONET?
- Part 2. What can WHONET do?
- Part 3. What is BacLink?
- Part 4. What's next?

Part 1. What is WHONET?

WHONET is a free software developed by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance for laboratory-based surveillance of infectious diseases and antimicrobial resistance.

The principal goals of the software are:

- to enhance local use of laboratory data; and
- to promote national and international collaboration through the exchange of data.

WHONET can be used by individual laboratories or as part of a national and international surveillance network. At present, the software, available in 44 languages, is used in over 130 countries around the world managing data from over 2300 clinical, public health, veterinary, and food laboratories.

WHONET analytical tools facilitate:

- the understanding of the local epidemiology of microbial populations;
- the selection of antimicrobial agents;
- the identification of hospital and community outbreaks; and
- the recognition of quality assurance problems in laboratory testing.

Note: At present, WHONET can handle results from the testing of bacteria, fungi, and parasites. WHONET does not yet have virological tests incorporated, but this is a priority area of programming in the upcoming year.




Figure 2. Distribution of MRSA isolates by department. Only the first isolate per patient is included. The graph depicts the graph for the department of medicine.

Acinetobacter baumannii




Figure 3. Monthly distribution of patients with *Acinetobacter baumannii* over a two year period.




Figure 4. %RIS and test measurement statistics for *K. pneumoniae*. %Resistant results are shown to the left for all antimicrobials, including the 95% confidence interval. The graph to the right depicts the distribution of disk diffusion zone diameters around the gentamicin disk.




Figure 5. Ciprofloxacin %Resistant results for all *Enterobacteriaceae*.




Figure 5. Scatterplot comparison of gentamicin and amikacin results for *K. pneumoniae*. To the left is a comparison of the disk diffusion zone diameter results. To the right is the comparison using the test interpretations – resistance, intermediate, and susceptible.

sau: PEN OXA CLI ERY GEN AMK TCY




Figure 6. Resistance profiles. Monthly distribution of patients with isolates of *S. aureus* of the indicated resistance phenotype. The isolates are non-susceptible to PEN, OXA, CLI, ERY, GEN, AMK, and TCY, but susceptible to CHL and VAN.

Analysis Results								
File Edit Data								
Copy table		Copy graph		Print table		Print graph		Continue
Organism = All organisms (n=427 Isolates)								
Specimen type: bl								
Number	Organisms	Alert	Number of isolates	Priority	Quality control	Important species	Important resistance	
8	All organisms	Discordant penicillin and beta-lactam+inhibitor resul	57	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10	All organisms	Discordant quinolone and fluoroquinolone results	1	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
12	Anaerobes	Non-susceptible to metronidazole	10	High priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
27	Enterobacteriaceae	Discordant aminoglycoside results	4	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
28	Enterobacteriaceae	Discordant first-, second-, and third-generation cephr	4	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
30	Enterobacteriaceae	Probable ESBL-producing Enterobacteriaceae	18	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
31	Enterobacteriaceae	Non-susceptible to amikacin	5	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
32	Enterobacteriaceae	Non-susceptible to carbapenems	3	High priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
33	Enterobacteriaceae	Non-susceptible to fluoroquinolones	20	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
35	Enterococcus faecalis	Non-susceptible to penicillins	31	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
37	Enterococcus sp.	VRE -Vancomycin-resistant Enterococcus	15	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
61	Listeria monocytogenes	Important species	3	High priority	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
90	Salmonella sp.	Important species	3	Medium priority	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
104	Shigella sp.	Non-susceptible to colistin, polymyxin	1	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
107	Staphylococcus aureus	MRSA -Methicillin-resistant <i>S. aureus</i>	92	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
113	Staphylococcus sp.	Non-susceptible to vancomycin, teicoplanin by disk	210	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
117	Staphylococcus sp.	Non-susceptible to vancomycin, teicoplanin	210	High priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
123	Streptococcus pneumoniae	Beta-lactams tested by disk diffusion (except for oxa)	16	Medium priority	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
124	Streptococcus pneumoniae	Non-susceptible to fluoroquinolones	13	High priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
126	Streptococcus pneumoniae	<i>S. pneumoniae</i> Non-susceptible to penicillin, third-g	2	Medium priority	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Figure 7. A summary of the microbiological alerts observed in the analyzed data. Categories of alert include “Quality control”, “Important species”, “Important resistance”, “Send to a reference laboratory”, and “Alert the infection control” among others.

Part 3. What is BacLink?

Many laboratories in the world already have computer systems for managing microbiological data. Examples include:

1. Simple desktop softwares such as Microsoft Excel, Access, or EpiInfo
2. Laboratory test instruments, such as Vitek, MicroScan, and SensiTitre
3. Commercial or in-house laboratory information systems.

Most of these systems were developed for purposes of clinical reporting, billing, and day-to-day specimen processing needs. Unfortunately, most systems have limited capabilities for analyzing data. This is where WHONET can be a valuable add-on to your existing system.

One way of getting data from your computer system into WHONET is through the manual re-entry of results directly into WHONET. But this can be a significant waste of valuable staff time and is subject to typing errors during the reentry of results.

To avoid reentering results into WHONET, we have developed the BacLink software. The purpose of the BacLink software is to facilitate the conversion of data from your computer system into WHONET. You could do this interactively on a weekly, monthly, or *ad hoc* basis. In a number of institutions, it has also been possible to automate and schedule the entire process. BacLink is available free-of-charge from the World Health Organization as part of the WHONET package.

By using BacLink, you can thus avoid the manual entry of results into WHONET. A related benefit in the context of multi-center collaborations is the standardization of data from a number of incompatible data sources into one common structure that can be analyzed with WHONET.

To learn more about BacLink and its use, go through the “BacLink – Getting Started”.

Part 4. What’s next?

Now that you have installed WHONET, you are ready for the next steps.

If you plan on using WHONET for manual data entry, proceed with the WHONET tutorial on “Laboratory Configuration” followed by the tutorial on “Data Entry”.

If you want to download and convert data from an existing computer system, then it would be useful to continue with “BacLink – Getting Started”.

If you want to explore WHONET’s data analysis features using the sample data that comes with WHONET or if you already have some WHONET data of your own, you may wish to skip directly to the tutorial “Data Analysis 1”.